GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (NAS:XENE) » Definitions » E10

Xenon Pharmaceuticals (Xenon Pharmaceuticals) E10 : $-1.68 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Xenon Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.620. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.68 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-14), Xenon Pharmaceuticals's current stock price is $40.58. Xenon Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $-1.68. Xenon Pharmaceuticals's Shiller PE Ratio of today is .


Xenon Pharmaceuticals E10 Historical Data

The historical data trend for Xenon Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenon Pharmaceuticals E10 Chart

Xenon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -1.27 -1.66

Xenon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.32 -1.38 -1.55 -1.66 -1.68

Competitive Comparison of Xenon Pharmaceuticals's E10

For the Biotechnology subindustry, Xenon Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenon Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's Shiller PE Ratio falls into.



Xenon Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xenon Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.62/125.4675*125.4675
=-0.620

Current CPI (Mar. 2024) = 125.4675.

Xenon Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 0.000 99.473 0.000
201409 0.265 99.394 0.335
201412 0.664 98.367 0.847
201503 -0.640 99.789 -0.805
201506 -0.070 100.500 -0.087
201509 -0.270 100.421 -0.337
201512 -0.270 99.947 -0.339
201603 -0.230 101.054 -0.286
201606 -0.420 102.002 -0.517
201609 -0.510 101.765 -0.629
201612 -0.320 101.449 -0.396
201703 -0.430 102.634 -0.526
201706 -0.410 103.029 -0.499
201709 -0.430 103.345 -0.522
201712 -0.450 103.345 -0.546
201803 -0.210 105.004 -0.251
201806 -0.450 105.557 -0.535
201809 -0.630 105.636 -0.748
201812 -0.290 105.399 -0.345
201903 -0.420 106.979 -0.493
201906 -0.370 107.690 -0.431
201909 -0.330 107.611 -0.385
201912 -0.410 107.769 -0.477
202003 -0.220 107.927 -0.256
202006 -0.005 108.401 -0.006
202009 -0.250 108.164 -0.290
202012 -0.340 108.559 -0.393
202103 -0.420 110.298 -0.478
202106 -0.510 111.720 -0.573
202109 -0.360 112.905 -0.400
202112 -0.480 113.774 -0.529
202203 -0.350 117.646 -0.373
202206 -0.550 120.806 -0.571
202209 -0.570 120.648 -0.593
202212 -0.570 120.964 -0.591
202303 -0.630 122.702 -0.644
202306 -0.720 124.203 -0.727
202309 -0.730 125.230 -0.731
202312 -0.640 125.468 -0.640
202403 -0.620 125.468 -0.620

Add all the adjusted EPS together and divide 10 will get our e10.


Xenon Pharmaceuticals  (NAS:XENE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Xenon Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenon Pharmaceuticals (Xenon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Executives
Gary Patou director
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Justin D. Gover director SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Steven Gannon director C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
Simon N. Pimstone director 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Ian Mortimer director, officer: PRESIDENT & CEO C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Christopher John Kenney officer: Chief Medical Officer 200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W
Andrea Difabio officer: Chief Legal Officer BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Sherry Aulin officer: Chief Financial Officer 200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W
Sherrington Robin officer: SVP Bus. & Corp. Development C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
James R. Empfield officer: SVP, Drug Discovery 200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W
Seggern Christopher Von officer: Chief Commercial Officer 200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W